Pharmasset to Present at Two Upcoming Investor Conferences

Jun 07, 2010, 07:00 ET from Pharmasset, Inc.

PRINCETON, N.J., June 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Jefferies 2010 Global Life Sciences Conference being held June 9 to 11, 2010 at the Grand Hyatt, New York, NY and the ThinkEquity Mid Year Check-Up on Healthcare Conference being held June 16, 2010 at the Princeton Club, NY. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the Jefferies conference on Friday, June 11, 2010 at 12:45 PM (ET) and Patrick Higgins, EVP of Marketing and Sales, will provide an overview of the company at the ThinkEquity conference on Wednesday June 16, 2010 at 10:30 AM (ET).

To access simultaneous webcasts of Mr. Price's and Mr. Higgins's overviews via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentations to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcasts will be available on Pharmasset's website for thirty days following the conferences. The investor presentations will be available for download in PDF format immediately following the presentations in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside for chronic HCV infection, is in two Phase 2b clinical trials in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently completed a Phase 2a trial, and PSI_938, an unpartnered guanine analog in Phase 1.  We also have in our pipeline an additional guanine nucleotide analog, PSI-661, an isomer of PSI-879, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical trial.

Pegasys® and Copegus® are registered trademarks of Roche.

Contact

   Richard E. T. Smith, Ph.D.

   VP, Investor Relations and Corporate Communications

   Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," including, without limitation, statements  that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 and our Quarterly Reports on Form 10-Q for the periods ended December 31, 2009 and March 31, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.



RELATED LINKS

http://www.pharmasset.com